EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer

Xiaonan Xiang, Fei Wang, Yanbin Shen, Sheng Dai

Journal for ImmunoTherapy of Cancer · 2025-12 · 13 (12) · e013145

DOI: 10.1136/jitc-2025-013145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.12.2025. Verfasst von Xiaonan Xiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Drug Resistance, Neoplasm, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) is a multifunctional scavenger receptor expressed on tumor-associated macrophages (TAMs). In a recent study published in the Journal for ImmunoTherapy of Cancer , Yu et al reported that CLEVER-1 + TAMs accumulate in advanced gastric cancer (GC), associate with poor prognosis, and contribute to resistance to chemoimmunotherapy. CLEVER-1 blockade using bexmarilimab reprogrammed TAMs toward a pro-inflammatory phenotype by suppressing peroxisome proliferator-activated receptor gamma (PPARγ)-driven lipid metabolism and enhancing antigen presentation and inflammatory cytokine secretion. CLEVER-1 blockade also synergized with anti-programmed cell death protein 1 (PD-1) therapy in ex vivo GC models, particularly in tumors enriched with CLEVER-1 + TAM. These findings identify CLEVER-1 + TAMs as both biomarker and functional mediator of anti-PD-1 therapy resistance, providing a rationale for combining bexmarilimab with immune checkpoint blockade in GC. In this commentary, we discuss the mechanistic significance, translational potential, and clinical prospects of CLEVER-1 blockade to overcome immunotherapy resistance in GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsDrug Resistance, NeoplasmProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsTumor-Associated MacrophagesHumansAnimalsImmunotherapy

Stichwörter der Autor:innen

Gastric CancerImmune Checkpoint InhibitorMacrophage

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Colorectal Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China.
  • Provincial Key Laboratory of Precise Diagnosis and Treatment of Abdominal Infection, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China.
  • Department of Colorectal Surgery, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China daimd@zju.edu.cn.

Zitieren

APA

Xiang, X., Wang, F., Shen, Y., & Dai, S. (2025). CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer. Journal for ImmunoTherapy of Cancer, 13(12), e013145. https://doi.org/10.1136/jitc-2025-013145

Vancouver

Xiang X, Wang F, Shen Y, Dai S. CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer. Journal for ImmunoTherapy of Cancer. 2025;13(12):e013145. doi:10.1136/jitc-2025-013145

BibTeX
@article{Xiang2025,
  author = {Xiang, Xiaonan and Wang, Fei and Shen, Yanbin and Dai, Sheng},
  title = {CLEVER-1 blockade reprograms TAMs to overcome anti-PD-1 resistance in gastric cancer},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {12},
  pages = {e013145},
  doi = {10.1136/jitc-2025-013145}
}
Kostenlos starten →